# Pizarra — PT-pseudo_c03b1168ff4d (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c03b1168ff4d
Task: 1

Encounter: Urology - outpatient on 05 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.165 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 47.17 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.75055045 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.

Vitals: weight 87 kg, height 184 cm, BMI 25.7, BP 143/82 mmHg, HR 81 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2006).

Chief complaint: Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment.

History: A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable.

Physical examination: Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema.

Patient info: ICT consultant; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 26/35 (severe LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Audiology — hearing test.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.64 +/- 0.15   (95% CI 0.34-0.94)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.94 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 7.8 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current PSA rise and PI-RADS 4 finding, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior positive biopsy status is a critical piece of information that the classifier did not weigh against the current high PSA (7.8 ng/mL) and PI-RADS 4 finding. Furthermore, the model did not process the prose of the mpMRI report, which is crucial for assessing lesion stability, as noted by the prior's limitation.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a probability of 0.64, which falls into the 'discuss' tier where the model genuinely cannot distinguish between the two answers. This uncertainty is exacerbated by the guideline criterion stating the decision is undetermined by the panel. A suggestion of biopsy could be wrong if the patient falls into a low-risk category based on the retrieved documents (e.g., if the prior positive biopsy was for a very low-grade lesion, and the current PI-RADS 4 lesion is stable). The high aleatoric uncertainty (H=0.94) suggests the disagreement lies in the data itself, meaning the model cannot resolve the conflict between the rising PSA and the prior positive diagnosis.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size and zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 7.8 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline criterion states that the decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Spaarne Gasthuis (Haarlem) Radiology | 18 December 2024 | Multiparametric MRI of the Prostate. The report identifies a PI-RADS: 4 lesion in the left peripheral zone (base/mid), sized roughly 14 x 11 x 16 mm, with early focal enhancement. It notes no evidence of extracapsular extension or suspicious lymphadenopathy.
get_psa_trend
The serial PSA trend shows values: Jun 2022: 1.5 ng/mL, Sep 2023: 3.4 ng/mL, Jan 2025: 7.8 ng/mL.
get_previous_notes
The notes document a prior positive biopsy from January 2023. The patient is on ongoing monitoring, with the most recent note from September 2024 mentioning the PSA reached 7.8 ng/mL.

NOT RETRIEVED
The laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient context regarding the biopsy status, imaging stability, and PSA trajectory.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trend: 1.5 ng/mL (Jun 2022) $\rightarrow$ 3.4 ng/mL (Sep 2023) $\rightarrow$ 7.8 ng/mL (Jan 2025).
- Current PI-RADS 4 lesion identified on MRI.

AGAINST sampling this patient now:
- Prior biopsy result is documented, which complicates the decision.
- MRI report does not explicitly state if the PI-RADS 4 lesion is new or unchanged compared to a previous study.

WHERE THIS LEANS
The evidence shows a clear, documented rise in PSA and a PI-RADS 4 finding, which aligns with the statistical prior suggesting biopsy. This leans towards a recommendation for biopsy to further characterize the lesion given the clinical context.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (rising PSA trend and documented prior positive biopsy) supports a lean towards biopsy, resolving the ambiguity left by the initial protocol expert. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans towards biopsy because the retrieved evidence showed a clear serial PSA rise from 1.5 ng/mL to 7.8 ng/mL and the presence of a PI-RADS 4 lesion on the MRI. Although the prior positive biopsy complicates the decision, the lack of documentation regarding the prior grade or comparison against a previous MRI means the current findings warrant further characterization. The statistical prior suggested biopsy, and the retrieved data supports proceeding with sampling to determine the nature of the progression.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
